mRNA-1283

BIOLOGICAL4 trials

Sponsors

ModernaTX, Inc.

Conditions

SARS-CoV-2

Phase 1

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

CompletedNCT04813796

ModernaTX, Inc.SARS-CoV-2

Start: 2021-03-11End: 2023-07-25Updated: 2023-08-01

Phase 2

A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters

CompletedNCT05137236

ModernaTX, Inc.SARS-CoV-2

Start: 2021-12-06End: 2023-03-23Updated: 2025-07-17

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age

Not yet recruitingNCT07808697

ModernaTX, Inc.SARS-CoV-2

Start: 2026-09-01End: 2029-08-30Target: 300Updated: 2026-09-09

Phase 4

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

Active, not recruitingNCT07266558

ModernaTX, Inc.SARS-CoV-2

Start: 2025-11-26End: 2027-06-16Target: 30000Updated: 2026-04-28

Related Papers

Cell-Mediated Immunity of mRNA-1283 Vaccine Encoding SARS-CoV-2 Spike Receptor-Binding and N-Terminal Domains in Preclinical and Clinical Studies.

PubMed2026-06-04

Potent and dose-sparing next-generation SARS-CoV-2 vaccine, mRNA-1283, induces polyfunctional and durable T cell immunity

npj Vaccines2026-02-19

P-1510. The Next-Generation mRNA-1283 COVID-19 Vaccine Elicits Similar and Durable Cellular Immune Responses Compared With mRNA-1273

Open Forum Infectious Diseases2026-01-01

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine

The Journal of Infectious Diseases2025-01-1010 citations

Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial.

2024-09-0121 citations

Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2

Science Translational Medicine2023-09-1336 citations

Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults

Human Vaccines & Immunotherapeutics2023-01-0218 citations